Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
about
APOL1 Kidney Disease Risk Variants: An Evolving LandscapeAPOL1 toxin, innate immunity, and kidney injuryEpigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.Chronic kidney disease and risk of renal cell carcinoma: differences by race.Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseasesChanges in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseGene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer.The analysis of APOL1 genetic variation and haplotype diversity provided by 1000 Genomes project.Plasma biomarker proteins for detection of human growth hormone administration in athletes.Does copy number variation of APOL1 gene affect the susceptibility to focal segmental glomerulosclerosis?APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.APOLs with low pH dependence can kill all African trypanosomes.Autophagy and tight junction proteins in the intestine and intestinal diseases.APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase RRenal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
P2860
Q26799191-110B5208-CB40-4AEE-BDF7-2908B9009F6FQ28085667-FB67F127-0F85-4F63-81AE-486385A160C5Q34619389-D443C484-611C-4AAD-95F4-C36125B7260AQ35577000-64FA1DF3-BFF3-4EDD-A2DE-D43E375A1B95Q35813345-1A32DF2E-ECE4-4B84-8D0B-63F46483BAFAQ36994371-52386C21-457E-468B-A857-370A59B2C975Q37067687-213BB670-E9ED-475C-8305-F8AC3EDBC08EQ37723993-EB1DB842-877F-4B8C-BDC9-4AB08145B827Q38643676-345A4A9E-1D41-4553-A3A9-B6518292C4FDQ41565757-FF9E8073-30B4-4A24-8EA0-6C72DB2002D2Q46321479-5E06440E-983A-41DC-81D5-4834D150E23BQ46457437-922C274E-4347-4408-9E5E-F3C780DCAD8EQ47418676-AEA0DD37-E9A4-4143-89A5-421BBE045907Q47781656-9B394C96-9C38-4761-8D4A-F40A24B643CDQ54209817-35ECB841-F2EC-4091-9696-C565ECAD00F4Q58699823-E5A8DC2C-14D9-45BA-8DEA-C170CD64ABC6Q58762704-A829AAC4-9BFF-49AC-A616-960578F488F7
P2860
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@ast
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@en
type
label
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@ast
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@en
prefLabel
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@ast
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@en
P2093
P2860
P1433
P1476
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
@en
P2093
Chien-An A Hu
Edward I Klopfer
Patricio E Ray
P2860
P304
P356
10.1016/J.FEBSLET.2012.03.002
P407
P577
2012-03-08T00:00:00Z